Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Rhea-AI Summary

Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Conference on August 13, 2025.

CEO Mark L. Baum and CFO Andrew Boll will participate in a fireside chat at 8:30 a.m. ET. Additionally, Baum will join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET. Both sessions will be available via webcast on the company's website, with replays accessible for 90 days after the event.

News Market Reaction

-1.29%

1 alert

-1.29% News Effect

On the day this news was published, HROW declined 1.29%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5^th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.

Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. Eastern time.

Both the fireside chat and the panel will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Contact:
Mike Biega, Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

FAQ

When is Harrow (HROW) presenting at the H.C. Wainwright Ophthalmology Conference 2025?

Harrow will present on August 13, 2025, with a fireside chat at 8:30 a.m. ET and a panel discussion at 1:00 p.m. ET.

Who will be representing Harrow at the H.C. Wainwright Conference?

CEO Mark L. Baum and CFO Andrew Boll will represent Harrow at the conference, participating in a fireside chat. Baum will also join a panel on novel eye treatments.

How can investors access Harrow's H.C. Wainwright Conference presentation?

Investors can access the presentations via live webcast on Harrow's company website. A replay will be available for 90 days following the event.

What topics will Harrow (HROW) discuss at the H.C. Wainwright Conference?

Harrow will participate in a fireside chat and CEO Mark Baum will join a panel discussion on 'Novel Treatments for Front-of-the-Eye Indications'.